Related Experiment Videos
Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative
W G An1, R C Schnur, L Neckers
1Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Purpose:
Recently, it has been shown that geldanamycin (GA), a benzoquinone ansamycin, is able to deplete mutant p53, p185erbB2 and Raf-1 proteins in cancer cells. However, the relationship between these activities of GA and its antiproliferative activity is not clear. Here we investigated the effects of 28 GA derivatives in SKBr3, a human breast cancer cell line.
Methods:
We performed Western blot analysis of Raf-1, p185erbB2 and mutant p53 proteins following drug treatment and correlated these findings with the cytotoxicity of the various GA derivatives.
Results:
We found that downregulation of Raf-1, p185erbB2 and mutant p53 proteins was correlated. Thus, a drug that was active against one oncoprotein was equally active against the two others. Inactive derivatives were identified by their inability to downregulate these oncoproteins, even at a high dose (2 microM). These inactive drugs also had no or minimal antiproliferative activity (IC50 > 3 microM). All other analogs (at a concentration of 2 microM) downregulated p53, p185erbB2, and Raf-1, and also displayed cytotoxicity (IC50 in the range 6-600 nM). This category of drugs was further divided into more- and less-active agents by testing at lower doses (40 nM). The drugs that remained active against their molecular targets had an IC50 for antiproliferative activity of less than 40 nM. Maximal effects on mutant p53, p185erbB2 and Raf-1 were observed at doses that were 4-5 times greater than the cytotoxic IC50.
Conclusions:
These findings suggest that GA and its derivatives are cytostatic/cytotoxic at concentrations that also downregulate Raf-1, p185erbB2 and mutant p53, and raise the possibility that depletion of these proteins and the antiproliferative activities of GA have a common mechanism.
Insights
Geldanamycin derivatives deplete cancer-related proteins like mutant p53, p185erbB2, and Raf-1. This protein depletion is directly linked to their antiproliferative effects in cancer cells, suggesting a common mechanism.
Area of Science:
- Molecular Oncology
- Cancer Therapeutics
- Drug Discovery
Background:
- Geldanamycin (GA) is known to deplete specific oncoproteins (mutant p53, p185erbB2, Raf-1) in cancer cells.
- The precise relationship between GA's oncoprotein depletion and its antiproliferative activity remains unclear.
- Investigating GA derivatives is crucial for understanding their therapeutic potential.
Purpose of the Study:
- To investigate the effects of 28 geldanamycin (GA) derivatives on cancer cell lines.
- To determine the correlation between oncoprotein depletion and antiproliferative activity of GA derivatives.
- To identify key molecular targets for GA-mediated cancer cell death.
Main Methods:
- Western blot analysis was used to assess the levels of Raf-1, p185erbB2, and mutant p53 proteins.
- Drug treatment with various GA derivatives was performed on SKBr3 human breast cancer cells.
- Cytotoxicity assays (IC50 determination) were correlated with protein downregulation.
Main Results:
- Downregulation of Raf-1, p185erbB2, and mutant p53 proteins by GA derivatives was found to be correlated.
- Inactive GA derivatives failed to downregulate these oncoproteins and exhibited minimal antiproliferative activity (IC50 > 3 microM).
- Active GA derivatives (IC50 6-600 nM) effectively downregulated all three oncoproteins, with maximal effects observed at doses 4-5 times the cytotoxic IC50.
Conclusions:
- Geldanamycin (GA) and its derivatives exhibit cytostatic/cytotoxic effects at concentrations that also downregulate Raf-1, p185erbB2, and mutant p53.
- These findings strongly suggest a common mechanism underlying both oncoprotein depletion and antiproliferative activity of GA derivatives.
- This study provides a basis for developing novel geldanamycin-based cancer therapies targeting multiple oncoproteins.